131.00
-4.00 (-2.96%)
EUR · F
52-week range
99.42
141.00
Trading at 76% of the 52-week range
Market Cap
256.60B
P/E Ratio
24.95
Forward P/E
14.39
Book Value
19.52
Div. Yield
3.76%
% Institutions
7.26%
% Insiders
0.012%

1 Year

+24.3%

3 Year

+60.7%

10 Year

+247.7%
Description

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG

Actions

Add an action for NOTA.F, or sign in to see your action list.

Company Information

▼
Company Name
Novartis AG
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
F
Currency: EUR
Full Time Employees: 75,267
Phone: 41 61 324 11 11
Fiscal Year End: December
Description:

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG

Address:

Lichtstrasse 35, Basel, Switzerland, 4056

People

▼

Directors & Officers

Name Title Year Born
Dr. Vasant Narasimhan M.D. Chief Executive Officer 1976
Mr. Victor Bulto President of US 1978
Dr. Patrick Horber M.D. President of International 1970
Mr. Mukul Mehta Chief Financial Officer 1973
Dr. Steffen Lang Ph.D. President of Operations 1967
Paul Penepent Head of Group Financial Reporting and Accounting NA
Ms. Sloan Simpson Global Head of Investor Relations NA
Ms. Karen L. Hale Chief Legal & Compliance Officer 1968
Dr. Robert Kowalski Pharm.D. Chief People & Organization Officer 1968
Mr. Evan Beckman Global Head of Translational Medicine at Novartis Institute for BioMedical Research NA

Financial Highlights

▼
Market Cap: $256.60B
EBITDA: $23.10B
P/E Ratio: $24.95
PEG Ratio: $3.27
Book Value: $19.52
Dividend/Share: $4.67
Dividend Yield: 3.76%
Earnings/Share: $5.41
Profit Margin: 22.50%
Operating Margin: 34.62%
ROA (TTM): 10.25%
ROE (TTM): 30.35%
Revenue (TTM): $56.69B
Revenue/Share (TTM): $29.64
Earnings Growth (YOY): -17.00%
Revenue Growth (YOY): 0.80%

Valuation Metrics

Enterprise Value: $273.95B
Trailing P/E: 24.95
Forward P/E: 14.39

Shares Statistics

Shares Outstanding: 1.90B
Shares Float: 1.86B
% Insiders: 0.012%
% Institutions: 7.26%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$56.67B
Cost of Goods Sold
adjust
$-13.70B
Gross Profit
subtotal
$42.98B
SG&A
adjust
$-13.25B
R&D
adjust
$-11.20B
Other Operating Expense
adjust
$-14.58B
Operating Income
subtotal
$17.64B
Other / Non-Operating Items
adjust
$-3.66B
Net Income
subtotal
$13.98B

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about NOTA.F!